清髓性造血细胞移植中无钙调神经磷酸酶抑制剂干预慢性移植物抗宿主病的随机III期BMT CTN试验
多中心III期试验将346例急性白血病或骨髓增生异常患者随机分配至CD34选择外周血干细胞、骨髓移植后环磷酰胺或他克莫司联合甲氨蝶呤方案。无钙调神经磷酸酶抑制剂干预未优于对照组2年无复发生存率,CD34选择降低中重度慢性GVHD但增加移植相关死亡率。
要点
- CD34选择组2年无复发生存率50.6%,对照组41.0%,差异无统计学意义(HR 0.80,P=0.24)
- CD34选择组中重度慢性GVHD发生率更低(HR 0.25),但移植相关死亡率更高(HR 2.76)
- PTCy组慢性GVHD和生存结局与对照组相当,疾病复发有降低趋势(HR 0.52,P=0.037)
核心结论
- 本试验中的无钙调神经磷酸酶抑制剂干预与骨髓移植后他克莫司联合甲氨蝶呤相比,未获得更优的无复发生存率。
- 中重度慢性GVHD发生率的降低未转化为生存改善。
研究设计与样本
- 多中心III期随机试验,纳入急性白血病或骨髓增生异常且具有HLA匹配供者的患者。
- 随机分配至CD34选择外周血干细胞组、骨髓移植后环磷酰胺组或骨髓移植后他克莫司联合甲氨蝶呤对照组。
- 主要终点为中重度慢性GVHD或复发生存率(CRFS)。
- 共入组346例患者,327例接受造血细胞移植,300例按方案执行。
主要发现
- 意向性治疗分析中,2年CRFS率:CD34选择组50.6%(与对照组相比HR 0.80,95%CI 0.56-1.15,P=0.24);PTCy组48.1%(HR 0.86,95%CI 0.61-1.23,P=0.41);对照组41.0%。
- 相应总生存率:CD34选择组60.1%(HR 1.74,95%CI 1.09-2.80,P=0.02);PTCy组76.2%(HR 1.02,95%CI 0.60-1.72,P=0.95);对照组76.1%。
- CD34选择与较低的中重度慢性GVHD相关(HR 0.25,95%CI 0.12-0.52,P=0.02),但移植相关死亡率更高(HR 2.76,95%CI 1.26-6.06,P=0.01)。
- PTCy组慢性GVHD和生存结局与对照组相当,疾病复发有降低趋势(HR 0.52,95%CI 0.28-0.96,P=0.037)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Calcineurin inhibitors (CNI) are standard components of graft-versus-host disease (GVHD) prophylaxis after hematopoietic cell transplantation (HCT). Prior data suggested that CNI-free approaches using donor T-cell depletion, either by ex vivo CD34 selection or in vivo post-transplant cyclophosphamide (PTCy) as a single agent, are associated with lower rates of chronic GVHD (cGVHD). METHODS: This multicenter phase III trial randomly assigned patients with acute leukemia or myelodysplasia and an HLA-matched donor to receive CD34-selected peripheral blood stem cell, PTCy after a bone marrow (BM) graft, or tacrolimus and methotrexate after BM graft (control). The primary end point was cGVHD (moderate or severe) or relapse-free survival (CRFS). RESULTS: Among 346 patients enrolled, 327 received HCT, 300 per protocol. Intent-to-treat rates of 2-year CRFS were 50.6% for CD34 selection (hazard ratio [HR] compared with control, 0.80; 95% CI, 0.56 to 1.15; P = .24), 48.1% for PTCy (HR, 0.86; 0.61 to 1.23; P = .41), and 41.0% for control. Corresponding rates of overall survival were 60.1% (HR, 1.74; 1.09 to 2.80; P = .02), 76.2% (HR, 1.02; 0.60 to 1.72; P = .95), and 76.1%. CD34 selection was associated with lower moderate to severe cGVHD (HR, 0.25; 0.12 to 0.52; P = .02) but higher transplant-related mortality (HR, 2.76; 1.26 to 6.06; P = .01). PTCy was associated with comparable cGVHD and survival outcomes to control, and a trend toward lower disease relapse (HR, 0.52; 0.28 to 0.96; P = .037). CONCLUSION: CNI-free interventions as performed herein did not result in superior CRFS compared with tacrolimus and methotrexate with BM. Lower rates of moderate and severe cGVHD did not translate into improved survival.
引用
- Luznik L, Pasquini MC, Logan B, et al. Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2021. PMID: 34855460. doi:10.1200/JCO.21.02293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。